← Back to Search

Antifibrinolytic

EACA for Blood Cancers (PROBLEMA Trial)

Phase 2
Waitlist Available
Led By Ana G. Antun, MD, MSc
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

This trial is comparing EACA to standard platelet transfusions to see if it is more effective in preventing bleeding in thrombocytopenic patients with cancer.

Eligible Conditions
  • Blood Cancers
  • Low Platelet Count

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants Who Develop Major Bleeding Episodes

Side effects data

From 2017 Phase 4 trial • 246 Patients • NCT02030821
7%
Deep Infection
4%
Superficial Cellulitis
2%
Hematoma/Seroma
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tranexamic Acid (TXA) - Total Hip Arthroplasty
Epsilon-aminocaproic Acid (Amicar) - Total Hip Arthroplasty
Epsilon-aminocaproic Acid (Amicar) - Total Knee Arthroplasty
Tranexamic Acid (TXA) - Total Knee Arthroplasty

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Prophylactic EACAExperimental Treatment1 Intervention
Prophylactic EACA 1000 mg PO twice daily if platelets \< 20 x 10⁹/L
Group II: Platelet transfusionActive Control1 Intervention
Platelet transfusion if platelet count is \< 20 x 10⁹/L in the outpatient or \< 10 x 10⁹/L in the inpatient setting
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EACA
2011
N/A
~60

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,679 Previous Clinical Trials
2,583,637 Total Patients Enrolled
Ana G. Antun, MD, MSc5.02 ReviewsPrincipal Investigator - Emory University
Emory University
5Patient Review
Dr. Antun is outstanding. I trust her implicitly and have for many years. She's always been thorough, responsive, and kind. I highly recommend her.
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top